Jun 13, 2014 (Fast Lane via COMTEX) -- Below are five companies in the Biotechnology industry that underperformed yesterday on a relative basis. This analysis was compiled based on yesterday's trading activity as we search for stocks that have could possible underperform its peers going forward.
Ariad Pharmaceuticals (NASDAQ:ARIA) ranks first with a loss of 8.69%; MannKind (NASDAQ:MNKD) ranks second with a loss of 5.51%; and BioCryst Pharmaceuticals (NASDAQ:BCRX) ranks third with a loss of 3.07%.
Insmed (NASDAQ:INSM) follows with a loss of 2.79% and Vanda Pharmaceuticals (NASDAQ:VNDA) rounds out the bottom five with a loss of 2.54%.ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers. Less
Recent VNDA News
- Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024 • PR Newswire (US) • 04/30/2024 08:30:00 PM
- Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals • GlobeNewswire Inc. • 04/25/2024 12:05:51 PM
- Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation • PR Newswire (US) • 04/22/2024 11:13:00 PM
- Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan • PR Newswire (US) • 04/17/2024 02:21:00 PM
- Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak • PR Newswire (US) • 04/17/2024 01:02:00 PM
- Biotech Catches Major Premarket Bid Following FDA Approval • AllPennyStocks.com • 04/03/2024 02:25:00 PM
- Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder • PR Newswire (US) • 04/02/2024 10:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:31:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:50:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:48:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:47:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:46:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:46:00 PM
- Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia • PR Newswire (US) • 03/06/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 02:14:13 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 02:12:36 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 02:10:28 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 02:08:29 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 02:06:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:53:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:52:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:52:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:52:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:50:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:32:11 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM